Titlebook: Emerging Technologies for Diagnosing Alzheimer‘s Disease; Innovating with Care Marianne Boenink,Harro van Lente,Ellen Moors Book 2016 The E

Inclement

Understanding Cognitive Screening Tools: Navigating Uncertainty in Everyday Clinical Practicementia Commissioning for Quality and Innovation Framework (CQUIN), this tinkering work is constrained. The chapter concludes by reflecting on how the case of the CQUIN might inform the ways in which diagnostic innovation overall is dealt with responsibly.

令人不快

AUGER

細(xì)胞學(xué)

偏狂癥

deadlock

Valuing Diagnostic Innovations: Towards Responsible Health Technology Assessmentin on the current logic of valuing in HTA. It presents various empirical cases reporting on diagnostic innovations, and reflects on how HTA strategies, policies, and interventions for practitioners and users of diagnostic innovations could be more flexible and responsible.

Override

粘

The Case Studies of Senior Appointments underlie Alzheimer’s disease. The usual claim is that these tests are more reliable, less burdensome, faster and/or cheaper than existing diagnostic procedures. But most importantly, the novel tests are thought to reveal Alzheimer’s at an early stage, possibly even years before the onset of symptoms.

暫時(shí)中止

,Emerging Technologies for Diagnosing Alzheimer’s Disease: Innovating with Care, underlie Alzheimer’s disease. The usual claim is that these tests are more reliable, less burdensome, faster and/or cheaper than existing diagnostic procedures. But most importantly, the novel tests are thought to reveal Alzheimer’s at an early stage, possibly even years before the onset of symptoms.

同音

https://doi.org/10.1007/b102415to produce diagnostic innovations of questionable value. Wider patient and public engagement, together with robust, legitimate, and accountable regulatory regimes will be required to truly ‘innovate with care’.